Literature DB >> 12719453

National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents.

L D Liebowitz1, M Slabbert, A Huisamen.   

Abstract

AIMS: The susceptibility patterns of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Klebsiella pneumoniae, and Streptococcus pyogenes isolated from specimens submitted to 12 private laboratories in South Africa were determined.
METHODS: Minimum inhibitory concentration (MIC) determinations were performed on the isolates in the microbiology laboratory at Tygerberg Hospital according to the recommendations of the National Committee for Clinical Laboratory Standards (NCCLS).
RESULTS: According to the NCCLS breakpoints, 24% of 729 S pneumoniae isolates were sensitive, 30% intermediate, and 46% resistant to penicillin. Rates of macrolide resistance were high, with 61% of the pneumococci being resistant to clarithromycin and azithromycin. Co-trimoxazole resistance was also high, with 28% of pneumococcal strains being sensitive, 21% intermediate, and 51% resistant. beta Lactamase was produced by 7% of 736 H influenzae isolates and 91% of 256 M catarrhalis isolates. The quinolones, moxifloxacin and levofloxacin, were universally active against all isolates tested, which included S pneumoniae, H influenzae, M catarrhalis, K pneumoniae, and S pyogenes.
CONCLUSIONS: Haemophilus influenzae and S pneumoniae were the most commonly isolated organisms. Resistance to penicillin was one of the highest reported in the world (76%) in S pneumoniae, as was macrolide resistance in pneumonocci, although surprisingly, only 14% of S pyogenes were resistant. The quinolones, moxifloxacin and levofloxacin, were active against all organisms tested, including the penicillin and macrolide resistant strains and moxifloxacin was more active than levofloxacin against pneumococci.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12719453      PMCID: PMC1769954          DOI: 10.1136/jcp.56.5.344

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  17 in total

Review 1.  Streptococcus pneumoniae respiratory tract infections.

Authors:  K P Klugman; C Feldman
Journal:  Curr Opin Infect Dis       Date:  2001-04       Impact factor: 4.915

2.  Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000.

Authors:  Laura M Koeth; Michael R Jacobs; Saralee Bajaksouzian; Anne Zilles; Gengrong Lin; Peter C Appelbaum
Journal:  Int J Antimicrob Agents       Date:  2002-01       Impact factor: 5.283

3.  Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.

Authors:  M E Jones; A M Staples; I Critchley; C Thornsberry; P Heinze; H D Engler; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

4.  Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.

Authors:  J M Blondeau; D Vaughan; R Laskowski; S Borsos
Journal:  Int J Antimicrob Agents       Date:  2001-06       Impact factor: 5.283

5.  Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.

Authors:  A Pong; K S Thomson; E S Moland; S A Chartrand; C C Sanders
Journal:  J Antimicrob Chemother       Date:  1999-11       Impact factor: 5.790

Review 6.  Surveillance of resistance in bacteria causing community-acquired respiratory tract infections.

Authors:  David Felmingham; C Feldman; W Hryniewicz; K Klugman; S Kohno; D E Low; C Mendes; A C Rodloff
Journal:  Clin Microbiol Infect       Date:  2002       Impact factor: 8.067

Review 7.  The drug-resistant pneumococcus: clinical relevance, therapy, and prevention.

Authors:  J I Harwell; R B Brown
Journal:  Chest       Date:  2000-02       Impact factor: 9.410

8.  The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections.

Authors:  D Felmingham; R N Grüneberg
Journal:  J Antimicrob Chemother       Date:  2000-02       Impact factor: 5.790

9.  Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999).

Authors:  L M Deshpande; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2000-06       Impact factor: 2.803

10.  Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: results of a Canadian national surveillance study. The Canadian Respiratory Infection Study Group.

Authors:  G G Zhanel; J A Karlowsky; L Palatnick; L Vercaigne; D E Low; D J Hoban
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

View more
  13 in total

1.  Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice.

Authors:  T Schaberg; M Möller; T File; K Stauch; H Landen
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

2.  Is Streptococcus pyogenes resistant or susceptible to trimethoprim-sulfamethoxazole?

Authors:  Asha C Bowen; Rachael A Lilliebridge; Steven Y C Tong; Robert W Baird; Peter Ward; Malcolm I McDonald; Bart J Currie; Jonathan R Carapetis
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

3.  Microbiology of lower respiratory tract infections in benin city, Nigeria.

Authors:  Christopher Aye Egbe; Casimir Ndiokwere; Richard Omoregie
Journal:  Malays J Med Sci       Date:  2011-04

Review 4.  Risk Factors for Drug-Resistant Cap in Immunocompetent Patients.

Authors:  Francisco Arancibia; Mauricio Ruiz
Journal:  Curr Infect Dis Rep       Date:  2017-03       Impact factor: 3.725

5.  Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa.

Authors:  Christopher J Hoffmann; Katherine L Fielding; Salome Charalambous; Craig Innes; Richard E Chaisson; Alison D Grant; Gavin J Churchyard
Journal:  AIDS       Date:  2010-07-17       Impact factor: 4.177

Review 6.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 7.  Moxifloxacin: a review of its use in the management of bacterial infections.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Efficacy and tolerability of sequential intravenous/oral moxifloxacin therapy in pneumonia: results of the first post-marketing surveillance study with intravenous moxifloxacin in hospital practice.

Authors:  J Barth; K Stauch; H Landen
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

9.  A situational analysis of antimicrobial drug resistance in Africa: are we losing the battle?

Authors:  Andrew Nyerere Kimang'a
Journal:  Ethiop J Health Sci       Date:  2012-07

10.  Ten years of surveillance for invasive Streptococcus pneumoniae during the era of antiretroviral scale-up and cotrimoxazole prophylaxis in Malawi.

Authors:  Dean B Everett; Mavuto Mukaka; Brigitte Denis; Stephen B Gordon; Enitan D Carrol; Joep J van Oosterhout; Elizabeth M Molyneux; Malcolm Molyneux; Neil French; Robert S Heyderman
Journal:  PLoS One       Date:  2011-03-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.